These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31578317)

  • 41. Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group.
    Kutny MA; Alonzo TA; Gamazon ER; Gerbing RB; Geraghty D; Lange B; Heerema NA; Sung L; Aplenc R; Franklin J; Raimondi SC; Hirsch BA; Konkashbaev A; Cox NJ; Onel K; Gamis AS; Meshinchi S
    Leukemia; 2015 Dec; 29(12):2424-6. PubMed ID: 26126966
    [No Abstract]   [Full Text] [Related]  

  • 42. [WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome successfully treated with the CAG regimen].
    Nakamura Y; Arai Y; Gunji H; Arai H; Nakamura F; Handa T; Tadokoro J; Maki K; Saito K; Mitani K
    Rinsho Ketsueki; 2002 Oct; 43(10):960-2. PubMed ID: 12462034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
    Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
    Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database.
    Xu J; Zhang Y; Hu J; Ren Y; Wang H
    Hematology; 2020 Dec; 25(1):79-84. PubMed ID: 32019476
    [No Abstract]   [Full Text] [Related]  

  • 45. Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.
    Bloomfield CD; Ruppert AS; Mrózek K; Kolitz JE; Moore JO; Mayer RJ; Edwards CG; Sterling LJ; Vardiman JW; Carroll AJ; Pettenati MJ; Stamberg J; Byrd JC; Marcucci G; Larson RA;
    Ann Hematol; 2004; 83 Suppl 1():S84-5. PubMed ID: 15124687
    [No Abstract]   [Full Text] [Related]  

  • 46. Landscape of TET2 mutations in acute myeloid leukemia.
    Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
    Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
    Goryainova NV
    Lik Sprava; 2014 Dec; (12):10-8. PubMed ID: 26638462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Expression of WT1 gene in children with acute myeloid leukemia].
    Tang X; Guo X; Yang X; Xiao H; Sun JJ; Yuan LX; Gao J
    Zhongguo Dang Dai Er Ke Za Zhi; 2016 Dec; 18(12):1211-1216. PubMed ID: 27974109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
    Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations.
    Merdin A; Dal MS; Çakar MK; Yildiz J; Ulu BU; Batgi H; Tetik A; Seçilmiş S; Darçin T; Şahin D; Bakirtaş M; Başçi S; Yiğenoğlu TN; Baysal NA; İskender D; Altuntaş F
    Medicine (Baltimore); 2020 Apr; 99(14):e19627. PubMed ID: 32243389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
    Zidan MA; Kamal Shaaban HM; Elghannam DM
    Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deletion of TET2 gene in an acute myeloid leukemia case with a t(4;15)(q24;q26) characterized by glass needle based chromosome microdissection and oligonucleotide array.
    Villa O; Mallo M; Kosyakova N; Salido M; Liehr T; Martínez-Avilés L; Pedro C; García-Aragonés M; Espinet B; Bellosillo B; Florensa L; Arenillas L; Cuscó I; Jurado LA; Solé F
    Leuk Res; 2011 Sep; 35(9):e161-3. PubMed ID: 21684005
    [No Abstract]   [Full Text] [Related]  

  • 53. Molecular analysis of WT1 and KIT mutations in patients from an Indian population with de novo acute myeloid leukemia: determination of incidence, distribution patterns, and report of a novel KIT mutation.
    Ahmad F; D'Souza W; Mandava S; Das BR
    Leuk Lymphoma; 2011 May; 52(5):865-76. PubMed ID: 21504297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
    Miglino M; Colombo N; Pica G; Grasso R; Clavio M; Bergamaschi M; Ballerini F; Ghiso A; Ghiggi C; Mitscheunig L; Beltrami G; Cagnetta A; Vignolo L; Lucchetti MV; Aquino S; Pierri I; Sessarego M; Carella AM; Gobbi M
    Leuk Lymphoma; 2011 Oct; 52(10):1961-9. PubMed ID: 21942328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical significance of TET2 gene expression in 157 adult acute myeloid leukemia patients with normal cytogenetics].
    Zhu Z; Chen J; Yu M; Chen F; Chen Z; Lou J; Tong H; Huang J; Qian W; Meng H; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):802-7. PubMed ID: 25246247
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.
    Yamazaki J; Taby R; Jelinek J; Raynal NJ; Cesaroni M; Pierce SA; Kornblau SM; Bueso-Ramos CE; Ravandi F; Kantarjian HM; Issa JP
    J Natl Cancer Inst; 2015 Nov; 108(2):. PubMed ID: 26568194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Yasukawa M; Fujiwara H; Ochi T; Suemori K; Narumi H; Azuma T; Kuzushima K
    Am J Hematol; 2009 May; 84(5):314-5. PubMed ID: 19338044
    [No Abstract]   [Full Text] [Related]  

  • 59. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
    Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
    Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia.
    Konstandin N; Bultmann S; Szwagierczak A; Dufour A; Ksienzyk B; Schneider F; Herold T; Mulaw M; Kakadia PM; Schneider S; Spiekermann K; Leonhardt H; Bohlander SK
    Leukemia; 2011 Oct; 25(10):1649-52. PubMed ID: 21625234
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.